BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
Conditions:  Advanced Malignant Solid Neoplasm;  Metastatic Carcinoma in the Liver;  Metastatic Carcinoma in the Lung;  Metastatic Malignant Neoplasm in the Thoracic Cavity;  Metastatic Malignant Solid Neoplasm Interventions:  Drug: Anti-GITR Agonistic Monoclonal Antibody BMS-986156;  Biological: Ipilimumab;  Biological: Nivolumab;  Radiation: Stereotactic Body Radiation Therapy Sponsors:  M.D. Anderson Cancer Center;  National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver | Liver Cancer | Radiation Therapy | Research | Urology & Nephrology | Yervoy